Inaspir Accuhaler

Salmeterol, the active ingredient in Inaspir Accuhaler, is a long‑acting β2‑adrenergic agonist presented as a 50 µg per inhalation dry‑powder inhaler (Accuhaler) for inhalation use. It provides maintenance bronchodilation for patients with asthma and chronic obstructive pulmonary disease (COPD).

GNH USA supplies Inaspir Accuhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare facilities worldwide.

Salmeterol is a long‑acting bronchodilator that acts on the β2‑adrenergic pathway to improve airflow in chronic respiratory diseases. - Asthma: improves symptom control and reduces the frequency of exacerbations when used as maintenance therapy. - Chronic obstructive pulmonary disease (COPD): provides sustained bronchodilation to enhance lung function and exercise tolerance.

Common and serious adverse reactions have been reported with Salmeterol inhalation.

Common Side Effects: - Throat irritation or dryness - Cough - Headache - Tremor - Palpitations - Muscle cramps

Serious or Rare Side Effects: - Paradoxical bronchospasm - Severe allergic reaction (anaphylaxis) - Cardiac arrhythmia - Chest pain or angina - Hypokalemia - Acute worsening of asthma symptoms

When prescribing or using Inaspir Accuhaler, several safety considerations should be observed. - Assess disease control: confirm that asthma or COPD is not adequately managed with other therapies before initiating. - Use as maintenance only: do not rely on Salmeterol for acute symptom relief. - Monitor cardiovascular status: observe for tachycardia, palpitations or hypertension during treatment. - Avoid concomitant non‑selective β‑blockers: they may diminish bronchodilator efficacy. - Review concomitant medications: consider potential interactions with diuretics or theophylline. - Store at below 25°C: keep in the original packaging, protect from moisture and heat.

Salmeterol may interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Non‑selective β‑blockers: can block the bronchodilatory action of Salmeterol. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure and risk of adverse effects. - Monoamine oxidase inhibitors: concurrent use may increase the risk of severe bronchospasm.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypokalemia, especially when combined with β2‑agonist activity. - Theophylline: additive stimulant effects on the cardiovascular system may occur. - Other long‑acting β2‑agonists or LABA‑containing combinations: increase the likelihood of overlapping side effects.